Pharmaceuticals - Generic / Specialty
Merck & Co Inc announces FDA approves RAGWITEK Sublingual tablet as immunotherapy to treat short ragweed Pollen-Induced Allergic Rhinitis with or without conjunctivitis in adults
Merck & Co Inc:U.S. Food and Drug Administration (FDA) has approved RAGWITEK (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U).RAGWITEK is allergen extract indicated as immunotherapy for treatment of short ragweed pollen-induced allergic rhinitis with or without...
GlaxoSmithKline Plc and Genmab A/S receive FDA approval for Arzerra(r) (ofatumumab) as first-line treatment in combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia
GlaxoSmithKline Plc and Genmab A/S:U.S. Food and Drug Administration (FDA) has approved Supplemental Biologic License Application (sBLA) for use of Arzerra(r) (ofatumumab), a CD20-directed monoclonal antibody, in combination with chlorambucil for treatment of previously untreated patients with...
OPKO Health Inc:Acquires Inspiro Medical Ltd.Will add Inspiromatic dry powder inhaler, developed by Inspiro, in its growing product portfolio.
American Capital receives $210 mln from sale of SPL Acquisition Corp to Shenzhen Hepalink Pharmaceutical Co., Ltd
American Capital Ltd:Says its portfolio company SPL Acquisition Corp, was sold to Shenzhen Hepalink Pharmaceutical Co., Ltd.Received $291 mln in debt and equity proceeds, including escrows and expected tax refunds, and realized a gain of $59 mln from transaction.Of the total proceeds, received $210...
No related earnings announcements are currently scheduled within the next 7 days.